Tumour type | Unique genetic event | Modern cure rate for metastatic disease | Standard drugs | Reference |
---|---|---|---|---|
Trophoblast tumours | Â | |||
Post Mole GTT | Nuclear Fusion | 100% | Methotrexate or Dactinomycin | [29] |
Gestational choriocarcinoma | Nuclear Fusion | 95% | Etoposide, Methotrexate Dactinomycin, Cyclophosphamide, Vincristine | [30] |
PSTT | Nuclear Fusion | 49% | Etoposide, Methotrexate Dactinomycin, Etoposide, Cisplatin | [31] |
Germ cell tumours | Â | |||
Testicular cancer | Meiosis | 90% | Bleomycin, Etoposide, Cisplatin | [32] |
Ovarian germ cell tumour | Meiosis | 81% | Bleomycin, Etoposide, Cisplatin | [33] |
Childhood malignancies | Â | |||
Wilms | Gastrulation | 80% | Dactinomycin, Vincristine, Doxorubicin | [34] |
Neuroblastoma | Gastrulation | 40–90% | Carboplatin, Etoposide, Cyclophosphamide, Doxorubicin | [35] |
Ewings | Gastrulation | 30% | Vincristine, Doxorubicin, Ifosfamide, Etoposide Busulphan Melphalan | [36] |
Acute leukemia | Â | |||
B ALL | VDJ rearrangement | Child 85% | Dexamethasone, Vincristine, Asparaginase Daunorubicin | |
Adult 53% | ||||
T ALL | VDJ rearrangement | Child 75% | Dexamethasone, Vincristine, Asparaginase Daunorubicin | [39] |
AML | VDJ rearrangement | 40% | Daunorubicin, Cytarabine | [40] |
B Cell malignancies | Â | |||
Hodgkin’s lymphoma | Somatic Hypermutation | 80% | Doxorubicin, Bleomycin Vinblastine Dacarbazine | [41] |
Diffuse large B cell lymphoma | Somatic Hypermutation | 75% (GCB) | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab | [42] |
40% (ABC) | ||||
Burkitt’s lymphoma | Somatic Hypermutation | 80% | Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Ifosfamide | [43] |
Etoposide, Cytarabine | ||||
T Cell malignancies | Â | |||
ALK + ve anaplastic large cell lymphoma | V(D)J rearrangement | 80% | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | [44] |